Last $8.37 USD
Change Today -0.1297 / -1.53%
Volume 36.0K
INO On Other Exchanges
As of 9:51 AM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

inovio pharmaceuticals inc (INO) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/24/14 - $15.80
52 Week Low
05/12/14 - $7.48
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

inovio pharmaceuticals inc (INO) Related Businessweek News

No Related Businessweek News Found

inovio pharmaceuticals inc (INO) Details

Inovio Pharmaceuticals, Inc., together with its subsidiaries, discovers, develops, and develops synthetic vaccines and immune therapies focusing on cancers and infectious diseases. The company’s DNA-based SynCon technology designed to provide protection against known and new unmatched strains of pathogens, such as influenza. Its electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. The company’s clinical programs include HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, and malaria vaccines. It is also advancing preclinical research for a seasonal/pandemic influenza vaccine, as well as other products. The company was formerly known as Inovio Biomedical Corporation and changed its name to Inovio Pharmaceuticals, Inc. in May 2010. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Blue Bell, Pennsylvania.

71 Employees
Last Reported Date: 03/17/14
Founded in 1979

inovio pharmaceuticals inc (INO) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $852.8K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $422.0K
Chief Operating Officer
Total Annual Compensation: $409.8K
Chief Medical Officer
Total Annual Compensation: $414.3K
Compensation as of Fiscal Year 2013.

inovio pharmaceuticals inc (INO) Key Developments

Inovio Pharmaceuticals, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015

Inovio Pharmaceuticals, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 . Venue: Westin St. Francis Hotel, San Francisco, California, United States.

Inovio Pharmaceuticals, Inc. Presents at 8th Annual OneMedForum 2015, Jan-12-2015

Inovio Pharmaceuticals, Inc. Presents at 8th Annual OneMedForum 2015, Jan-12-2015 . Venue: San Francisco Marriott Marquis, Parc 55 Wyndham, Union Square, San Francisco, California, United States.

Inovio Pharmaceuticals, Inc. Announces Results of Phase I Study of HIV Immunotherapy, PENNVAX®-B

Inovio Pharmaceuticals, Inc. announced that results from a 12-patient phase I study of Inovio's HIV immunotherapy, PENNVAX®-B, in HIV-infected patients revealed that immune response characteristics generated by the immunotherapy were similar to those observed in HIV-infected individuals who without treatment do not progress to further stages of the disease. These extremely rare individuals who self-regulate their HIV infection are called ‘long-term non-progressors’ and it is believed that part of their ability to control infection may lie in their unique immune responses. In this phase I study, Inovio's HIV immunotherapy, which had been previously tested only in disease prevention, drove the expansion of activated HIV-specific CD8+ T cells with functional characteristics similar to those of long-term non-progressors.  HIV targets the immune system, specifically CD4+ T cells, which are responsible for activating CD8+ killer T cells that can kill the virus and infected cells. Unfortunately, with fewer CD4+ and CD8+ T cells, most infected individuals are unable to fight the virus. Inovio's synthetic immunotherapy technology is very effective at generating disease-specific killer T cells in the body. In this phase I study, HIV-infected individuals whose viral load was already effectively suppressed using a highly active antiviral therapy (HAART) received a four-dose regimen of PENNVAX®-B. The investigators observed that the cell-killing substances granzyme B and perforin (both necessary to kill targeted cells and viruses) produced by activated CD8+ killer T cells were present in quantities and characteristics similar to those of long-term non-progressors. Another striking result of this HIV study was that PENNVAX®-B increased the number of HIV-specific CD8+ killer T cells displaying the receptor integrin, which is associated with the ability to carry T cells to the gastrointestinal tract (GIT). The GIT hosts 40%-65% of the body's total immune cells, hence is the most important target organ for HIV, which targets CD4+ T cells and hides in gut mucosa. The increased presence of integrin suggests the potential of such an immunotherapy to better fight or eradicate these reservoirs of HIV infection in the GIT. The therapy was well-tolerated and did not result in any adverse events.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INO:US $8.37 USD -0.1297

INO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $8.68 USD -0.4799
Dynavax Technologies Corp $16.88 USD -0.13
GenVec Inc $3.44 USD +0.01
Vical Inc $1.03 USD 0.00
ZIOPHARM Oncology Inc $8.31 USD -0.13
View Industry Companies

Industry Analysis


Industry Average

Valuation INO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 52.7x
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 42.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INOVIO PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at